Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27179751 | 0.89 | FOLH1 (0.35) | FOLH1DGAT1ALDH1A1MAPTPOLB | |
| SCHEMBL27180242 | 0.89 | ASGR1 (0.37) | FOLH1DGAT1ALDH1A1ASGR1 | |
| SCHEMBL27180661 | 0.86 | FOLH1 (0.33) | FOLH1DGAT1ASGR1 | |
| SCHEMBL27179340 | 0.85 | KMT2A (0.42) | FOLH1DGAT1ALDH1A1MAPTPOLB | |
| SCHEMBL27179566 | 0.84 | FOLH1 (0.33) | FOLH1DGAT1ASGR1 | |
| SCHEMBL27180244 | 0.78 | ASGR1 (0.38) | FOLH1DGAT1ALDH1A1ASGR1 | |
| SCHEMBL23705339 | 0.78 | MAPT (0.47) | FOLH1DGAT1ALDH1A1MAPTPOLB | |
| SCHEMBL27179319 | 0.78 | FOLH1 (0.37) | FOLH1DGAT1ALDH1A1MAPTPOLB | |
| SCHEMBL27179817 | 0.76 | ASGR1 (0.35) | FOLH1DGAT1ALDH1A1MAPTKDM4E | |
| SCHEMBL27180527 | 0.73 | ASGR1 (0.49) | ALDH1A1MAPTPOLBKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | FOLH1 1343/4885DGAT1 1955/4885ALDH1A1 3256/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | FOLH1 1343/4885DGAT1 1955/4885ALDH1A1 3256/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | FOLH1 1343/4885DGAT1 1955/4885ALDH1A1 3256/4885 |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | FOLH1 1343/4885DGAT1 1955/4885ALDH1A1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.